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ABSTRACT
The purpose of the present review is to provide an update about the
most common risk factors or medical conditions associated with renal
stone formation, the current methods available for metabolic investiga-
tion, dietary recommendations and medical treatment. Laboratory
investigation of hypercalciuria, hyperuricosuria, hyperoxaluria, cystinuria,
hypocitraturia, renal tubular acidosis, urinary tract infection and reduc-
tion of urinary volume is based on the results of 24-hr urine collection and
a spot urine for urinary sediment, culture and pH. Blood analysis for crea-
tinine, calcium and uric acid must be obtained. Bone mineral density has
to be determined mainly among hypercalciurics and primary hyper-
parathyroidism has to be ruled out. Current knowledge does not support
calcium restriction recommendation because it can lead to secondary
hyperoxaluria and bone demineralization. Reduction of animal protein
and salt intake, higher fluid intake and potassium consumption should be
implemented. Medical treatments involve the use of thiazides, allopuri-
nol, potassium citrate or other drugs according to the metabolic distur-
bances. The correction of those metabolic abnormalities is the basic tool
for prevention or reduction of recurrent stone formation. (Arq Bras
Endocrinol Metab 2006;50/4:823-831)
Keywords: Kidney stones; Nephrolithiasis; Hypercalciuria; Osteopenia;
Calcium; Oxalate
RESUMO
Calculose Renal: Causas, Avaliação e Tratamento Médico.
O propósito desta revisão é apresentar uma atualização sobre os fatores
de risco ou condições médica comuns associadas com a formação de
cálculos renais, os métodos atualmente disponíveis para investigação
metabólica, recomendações dietéticas e tratamento médico. A investi-
gação laboratorial para hipercalciúria, hiperuricosuria, hiperoxalúria,
cistinúria, hipocitratúria, acidose tubular renal, infecção do trato urinário
e redução do volume urinário, é baseada nos resultados das coleções
de urina de 24h e amostra isolada para sedimento urinário, cultura e pH.
Deve-se obter análises sanguíneas para creatinina, cálcio e ácido úrico.
Deve-se determinar a densidade mineral óssea especialmente entre
pacientes hipercalciúricos, e o hiperparatiroidismo primário deve ser
excluído. O conhecimento atual não endossa as recomendações de
restrição de cálcio, já que isto pode levar o hiperaxalúria secundária e
desmineralização óssea. Redução da ingesta de proteína animal e de
sal deve ser implementada junto com aumento da ingesta de líquidos e
do consumo de potássio. Tratamento medicamentoso envolve o uso de
tiazídicos, alopurinol, citrato de potássio ou outras drogas, conforme o
distúrbio metabólico. A correção dessas anormalidades metabólicas é
o instrumento básico para a prevenção ou redução da formação recor-
rente de cálculos. (Arq Bras Endocrinol Metab 2006;50/4:823-831)
Descritores: Cálculos renais; Nefrolitíase; Hipercalciúria; Osteopenia; Cál-
cio; Oxalato
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NEPHROLITHIASIS IS A COMMON clinical disorderaffecting up to 5% of the general population in the
USA. (1). The prevalence of renal stone disease has
been rising in both sexes, being estimated that about 5%
of American women and 12% of men will develop a kid-
ney stone at some time in their life (2). Nevertheless, in
certain areas of the world, as in the Middle East, the life-
time risk appears to be even higher (3). There has been
heightened awareness of renal stone disease in children
as well (4). Recurrence rates of 50% after 10 years and
75% after 20 years have been reported (5,6).
Clinical manifestations are characterized by lum-
bar pain of sudden onset (the location of pain depends
on the location of stone in the urinary tract) that may be
accompanied by nausea and vomiting, gross or micro-
scopic hematuria Diagnosis of renal stone in the acute
setting is beyond the scope of the present update but in
brief, is represented by urinalysis and imaging. Urinaly-
sis often reveals hematuria but the latter is absent in
approximately 9% of cases (7). Crystalluria is occasional
and the presence of leucocyturia may suggest associated
urinary tract infection. Unenhanced helical computed
tomography (CT) scan, the most sensitive and specific
radiographic test (8,9), is becoming the diagnostic pro-
cedure of choice to confirm the presence of kidney and
especially of ureteral stones (10). However, high doses
of radiation and elevated costs must be considered (11).
Since renal ultrasound (US) provides information about
obstruction (12) but may miss ureteral stones, the asso-
ciation of US with conventional abdominal X-ray may
help (13). Renal colic must be differentiated from mus-
culoskeletal pain, herpes zoster, pyelonephritis, appen-
dicitis, diverticulitis, acute cholecystitis, gynecologic dis-
ease, ureteral stricture or obstruction due to blood clot,
polycystic kidney disease.
Stone formation usually results from an imbal-
ance between factors that promote urinary crystalliza-
tion, and those that inhibit crystal formation and
growth (14). The main determinants of calcium
oxalate (CaOx) supersaturation are oxalate and calci-
um concentration, while the latter associated to uri-
nary pH determines calcium phosphate supersatura-
tion. Urinary pH itself is the main determinant of uric
acid supersaturation (14).
CAUSES
Approximately 80% of kidney stones contain calci-
um, and the majority of them are composed primar-
ily of calcium oxalate. Although most calcium
oxalate stones contain some calcium phosphate, only
5% have hydroxyapatite or brushite as their main
constituent and 10% contain some uric acid (15).
Pure uric acid, cystine and infection stones are less
common. Although composition of each stone cor-
relates with supersaturation values in the urine (16),
calculi are seldom found without an admixture of
many salts and not every passed stone can be
retrieved for chemical analysis. In addition, patients
may present multiple stones and in case of persis-
tence of small and unobstructive calculi after sponta-
neous elimination or surgical removal, the calculi
might not present exactly the same admixture as the
voided or removed ones. Since the prevention is
aimed to avert new stone formation and further
growth of the remaining calculi, evaluation of
patients should be rather directed toward identifying
urinary risk factors for stone formation or recurrence
with the goal of devising appropriate, individualized
therapy. Table 1 lists the most common causes of
renal stone disease. A more detailed view of the
pathogenesis mechanisms involved in stone forma-
tion is provided in two in-depth reviews, which have
recently been published (2,14).
Evaluation of a renal stone patient starts with a
detailed history focusing on occupation, dietary and
lifestyle habits, previous use of medications, family pre-
disposition, and history of recurrent urinary tract infec-
tion and underlying disorders that predisposes to
nephrolithiasis. Incidental finding of asymptomatic
stones on a radiograph/ultra-sound may also occur.
The majority of calcium oxalate stone formers
(SF) suffers from no systemic disease and can be
described as idiopathic calcium oxalate SF patients.
Metabolic abnormalities responsible for stone recur-
rence are currently identified in up to 90% of such
patients (17) and will be the focus of the present review.
METABOLIC EVALUATION
A complete or comprehensive urinary metabolic profile
to guide prophylaxis of stone recurrence, consisting of
two 24-hr urine samples for stone risk analysis as well as
an oral calcium load test has been advocated lately to be
time-consuming and expensive (18). In a very recent
cost-effectiveness analysis of medical management
strategies for nephrolithiasis by the group of Pak and his
associates (19), such comprehensive or detailed meta-
bolic evaluation offered no advantage in cost or efficacy
over a simple metabolic evaluation (single 24-hr urine
collection) with respect to treatment of recurrent stone
formers. Therefore, a simple metabolic evaluation con-
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sisting of a single 24-hour urine collection for analysis of
all urinary stone risk factors may be sufficient (20) for a
medical evaluation of urolithiasis. On the other hand,
Parks et al. (21) and others (22) reported that only one
24-hour urine specimen may lead to misdiagnosis of
common metabolic disturbances.
The routine laboratorial investigation among
urolithiasis patients includes the determination of uri-
nary parameters involved in stone formation such as
urinary calcium, oxalate, magnesium, citrate, uric acid,
sodium, potassium and creatinine (23). Spot urine for
urinary sediment and culture to rule out urinary tract
infection are also part of the investigation. Urinary pH
must be determined in a 12-hr fasting sample and a
venous blood gas analysis must be obtained to screen
for complete forms of distal Renal Tubular Acidosis.
When systemic acidosis is not present, an ammonium
chloride test is needed (24). A blood sample must be
obtained for serum creatinine, calcium (total or ion-
ized), phosphate and uric acid determinations. Bone
mineral density has to be assessed mainly among idio-
pathic hypercalciuria patients, due to the important
association of urinary calcium losses with low bone
mineral density (25,26). Since primary hyperparathy-
roidism has to be ruled out, serum PTH can be deter-
mined either in the same single blood collection or in
a further sample in case hypercalcemia has been detect-
ed in the former, in order to reduce costs. However,
intermittent high levels of serum calcium may repre-
sent mild forms of subtle primary hyperparathyroidism
(27). A qualitative colorimetric test in spot urine sam-
ples to evidence the presence of high amounts of cys-
tine with sodium nitroprussiate can serve as a screen-
ing method for cystinuria.
Idiopathic hypercalciuria
It is generally agreed that the oversaturation of urine
with calcium is one of the most important risk factors
for calcium nephrolithiasis. Primary hyperparathy-
roidism, the most common primary cause of resorptive
hypercalciuria, hence hypercalcemic, is present in less
than 1% of nephrolithiasis patients (28) and will be dis-
cussed in detail in another chapter in this issue. Con-
versely, idiopathic hypercalciuria (29) represents the
primary metabolic alteration in almost 50% of patients
(17). Idiopathic hypercalciuria (IH) is defined by levels
of urinary calcium excretion in a 24-hour urine sample
exceeding 300 mg/day (7.5 mmoL) in men or 250
mg/day (6.25 mmoL) in women or higher than 4 mg
(0.1 mmoL) per kilogram of body weight per day,
regardless of gender and age, in the absence of hyper-
calcemia (14,30). However, levels around 200 mg/day
or higher than 150 mg per gram of urinary creatinine
can also increase supersaturation in patients with recur-
rent stones (28). The increased daily urinary excretion
rate of calcium among patients with kidney stones was
first recognized by Flocks in 1939 (31) and subse-
quently in 1953, Albright et al. (32) introduced the
term Idiopathic Hypercalciuria (IH) to distinguish a
group of calcium stone formers (CSF) who exhibited
hypercalciuria without hypercalcemia, and did not have
a history of excessive vitamin D use, primary hyper-
parathyroidism, hyperthyroidism, renal tubular acido-
sis, sarcosidosis, other granulomas or malignancy.
An acute oral calcium load test, described in
1975 by Pak et al. (33), should clearly distinguish
between absorptive and renal (renal calcium leak) sub-
types of hypercalciuria. In a previous evaluation by our
group (34), a 24-hr urinary calcium excretion, under
Table 1. Risk factors for stone formation.
• Anatomic abnormalities: medullary sponge kidney, ureteropelvic junction stenosis, pyelo-ureteral duplication, polycystic
renal disease, etc.
• Epidemiological factors and genetic predisposition: dietary risk factors, climate, occupation, family history of stones.
• Excessive excretion of promoters of urinary crystallization: calcium (idiopathic hypercalciuria), oxalate (enteric hyperox-
aluria), uric acid (uric acid hyperexcretion).
• Abnormalities of urinary pH: renal tubular acidosis, gouty diathesis, infection stones (struvite stones caused by urea-split-
ting organisms).
• Reduced excretion of inhibitors of urinary crystallization: hypocitraturia.
• Metabolic syndrome and obesity: pure uric acid stones.
• Low urine volume: reduced intake or increased loss of water.
• Hypercalcemic disorders: primary hyperparathyroidism and other disturbances of calcium metabolism.
• Lithogenic drugs: triamterene, indinavir, sulfadiazine, uricosuric agents.
• Genetic monogenic diseases: primary hyperoxaluria, cystinuria, familial hiperuricosuria, monogenic hypercalciuric stone-
forming diseases (X-linked recessive hypercalciuric diseases complex, familial hypomagnesemia with hypercalciuria and
nephrocalcinosis, Bartter syndrome types III and IV, autosomal dominant hypocalcemic hypercalciuria, hypophos-
phatemia associated to hypercalciuria, etc.
• Inflammatory bowel disease and other intestinal malabsorption states.
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conditions of a mean usual calcium intake of around
500 mg/day, was determined in CSF patients who
previously presented an absorptive or renal response to
this test. We observed that the majority of them, 63
and 78% of each group, presented normocalciuria
rather than hypercalciuria. Since this apparently nor-
mal calcium excretion might have resulted from a
combination of high calcium absorption and low calci-
um intake, those patients where then challenged to a
higher calcium intake of 1,500 mg/day given as sup-
plement for one week. Regardless of whether there
was a former absorptive or renal-like response to the
acute load, the higher calcium intake disclosed the
presence of subpopulations sensitive to calcium intake
in previously normocalciuric patients. Conversely,
most of the hypercalciuric patients, when challenged
to a higher calcium intake did not present a further
increase in their urinary calcium, showing that under
conditions of low calcium intake, as is the case of the
Brazilian population (35), patients were already
excreting calcium in excess of their intake, hence being
considered as dietary calcium-independent. In addi-
tion, as the morning urinary fasting calcium/creati-
nine (Ca/Cr) ratio seemed to be the single parameter
which would distinguish between renal and absorptive
hypercalciuric patients, with a cutoff value of 0.11, we
repeated this determination in 31 patients (34) and
found that 87% of them changed their results from val-
ues higher than 0.11 to lower values. Taken together,
these data suggest that Absorptive and Renal Hyper-
calciuria should be considered the same rather than
two distinct entities, a hypothesis already raised by
Coe et al. (36) representing a systemic abnormality of
calcium homeostasis probably induced by a dysregula-
tion of 1,25(OH)2D3, leading to alterations in calcium
transport in the intestine, kidney and bone (28,37)
characterized by increased intestinal calcium absorp-
tion and bone resorption, as well as decreased renal
tubular calcium reabsorption.
Several series in the literature (38-46), includ-
ing the one from our group (47), have demonstrated
that BMD is reduced in IH patients. Some of them
have reported increase of bone resorption markers as
well (39,40,42,45,46). A histomorphometric study
undertaken by our group in 1994 (47) disclosed a low
bone volume, a tendency of low bone formation cou-
pled with increased bone resorption and delayed bone
mineralization in male hypercalciuric CSF patients.
Other bone biopsy reports showed conflicting data
regarding bone resorption, but all of them have sug-
gested low bone formation and a severe mineralization
defect in hypercalciuric patients (47-50). The underly-
ing mechanisms responsible for higher bone resorp-
tion and/or lower bone formation in this setting are
still unclear and the reasons for the mineralization
defect remain unknown if one considers that serum
levels of calcium, phosphorus and vitamin D are nor-
mal in these patients. Anyway, a population-based
study has shown a fourfold increase in vertebral frac-
ture risk among urolithiasis patients when compared
to the general population (51), and in a large cross-
sectional survey (Third National Health and Nutrition
Examination Survey, NHANES III), a history of kid-
ney stone was found to be associated with lower
femoral neck BMD and more prevalent wrist and spine
fractures in men after adjustments for age and body
mass index (52).
Whether idiopathic hypercalciuria is the result
of a primary bone disorder, a consequence of a per-
sisting negative calcium balance or a combination of
both still remains to be determined. Nevertheless,
bone status must be evaluated and followed up in
patients with IH.
Hyperuricosuria and uric acid nephrolithiasis
Hyperuricosuria is defined by uric acid excretion above
750 and 800 mg/day for women and men, respectively.
Its prevalence is highly variable among different series.
Hyperuricosuria may be secondary to uricosuric medica-
tions, myeloproliferative disorders, primary gout or con-
genital disorders. A high animal protein (especially
purines) may increase uric acid excretion and decrease uri-
nary pH. Uric acid supersaturation is strongly controlled
by urinary pH. Diarrheas states may predispose to uric
acid nephrolithiasis due to low urine volume and urinary
pH. Uric acid may provide heterogeneous nuclei for cal-
cium oxalate stone formation. The lower frequency of
pure uric acid stones, around 5%, may be ascribed to the
usual urine acidity, which favors calcium oxalate crystal-
lization instead. However, recent findings provided by
metabolic studies have indicated an association between
pure uric acid nephrolithiasis and insulin resistance
(53,54). Those patients present abdominal obesity, dys-
lipidemia, arterial hypertension, elevated fasting glucose
levels and lower glucose disposal rate, hyperuricemia,
normouricosuria, and low urinary pH (53). The latter
may explain stone formation despite of normouricosuria.
Potential mechanisms include impaired ammoniagenesis
caused by resistance to insulin action in proximal tubule
or substrate competition by free fatty acids (54).
Hypocitraturia
Low urinary citrate levels below 320 mg/day, hypoci-
traturia, occur in approximately 50% of adult SF
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patients (17), isolated or associated with other meta-
bolic disturbances. Hypocitraturia may result from dis-
tal renal tubular acidosis, chronic diarrheal syndrome,
hypokalemia, urinary tract infection, but mostly it is of
unknown etiology, namely idiopathic hypocitraturia.
Citrate binds calcium in a soluble salt inhibiting crys-
tallization and slowing stone formation.
Hyperoxaluria
Hyperoxaluria can be due to an enzymatic distur-
bance in oxalate biosynthesis but primary hyperox-
aluria type I, the prevailing type, is a rare genetic dis-
order. Most cases of increased urinary oxalate found
in CSF patients are represented by secondary or mild
hyperoxaluria, defined by levels of urinary oxalate
higher than 45 mg/day, with a reported frequency
of around 12%. Secondary hyperoxaluria is due to
either increased availability of substrate (ascorbic
acid, ethylene glycol, methoxyflurane), reduced
degradation of oxalate by intestinal bacteria or
intestinal hyperabsorption of oxalate (imbalance
between intraluminal calcium and oxalate as in
enteric hyperoxaluria or due to a low-calcium diet).
Enteric hyperoxaluria induced by fat and bile salt
malabsorption is the hallmark of hyperoxaluria due
to intestinal hyperabsorption of oxalate (55). The
gastrointestinal diseases that have been associated
with this entity are those characterized by an
absence or nonfunctioning of the small bowel
(enteritis, small bowel resection or bypass surgery)
and those causing defective absorption of fat or bile
acids (chronic pancreatitis, biliary cirrhosis, blind
loop syndrome and other diseases). Unabsorbed bile
acids and fatty acids form complexes with calcium in
the intestinal lumen, limiting the amount of free cal-
cium to bind oxalate, with a consequent increase in
intestinal oxalate absorption leading to hyperox-
aluria. Dietary calcium restriction may lead to hyper-
oxaluria through the same mechanism (56).
Other pathophysiological conditions occurring
alone in less than 2% of SF patients include distal Renal
Tubular Acidosis, Infection Stones and Cystinuria (17).
Distal Renal Tubular Acidosis (dRTA)
dRTA is characterized by alkaline fasting urine pH asso-
ciated to hypercloremic hypokalemic metabolic acidosis,
hypocitraturia, hypercalciuria and often bone disease
(24). Acquired forms may be secondary to different
tubulo-interstitial renal diseases, calcium disorders,
drugs and toxins, autoimmune diseases (especially Sjö-
gren syndrome), among others. Hereditary forms are
mostly associated with nephrocalcinosis (57).
Infection stones
Infection stones form in the setting of upper urinary
tract infection with urease-producing bacteria. Those
microorganisms hydrolyze urea producing ammonia
and hydroxide, increasing urinary pH and phosphate
that bind to magnesium to form a “triple-crystal” com-
posed of struvite (magnesium ammonium phosphate)
and/or calcium carbonate apatite. Those calculi usual-
ly grow as branched stones that occupy a large portion
of the collecting system, namely, staghorn calculi.
Cystinuria
Cystinuria is a rare autosomic recessive disorder char-
acterized by reduced renal tubular reabsorption of the
dibasic aminoacids cystine, ornithine, lysine and argi-
nine (58). Overexcretion of cystine leads to stone for-
mation because its solubility in the urine is very low
under normal urine pH.
TREATMENT
Dietary recommendations
In the past, calcium restriction became a very popular
recommendation, based on the high incidence of
hypercalciuria. However, a large prospective epidemi-
ological study conducted in healthy men with differ-
ent levels of calcium intake lead to a surprising obser-
vation that the lower was the calcium intake, the
higher was the incidence of stone formation (59).
Such unexpected effect had probably been ascribed to
a secondary increase in urinary oxalate due to the
decrease binding of oxalate to calcium in the gas-
trointestinal tract. In 2002, a five-year randomized
trial comparing the effect of two diets in hypercalci-
uric men with recurrent calcium oxalate stones and
hypercalciuria, showed that a restricted intake of ani-
mal protein and salt, combined with a normal calcium
intake, provided greater protection than the tradi-
tional low-calcium diet (60). Therefore, there are
many reasons why calcium restriction should be
avoided in hypercalciuric patients: lack of a clear dis-
tinction between absorptive and renal hypercalciuria,
induction of secondary hyperoxaluria, predisposition
to bone loss due to a negative calcium balance and
also because other nutrients like protein, sodium,
oxalate and potassium could affect calcium excretion
as well (61). With respect to oxalate intake, there have
been no studies demonstrating that restrictions in
oxalate intake effectively reduce the recurrence of
stones. The ability of oxalate-rich foods to augment
oxalate excretion depends not only on the oxalate
Renal Stone Disease
Heilberg & Schor
828 Arq Bras Endocrinol Metab vol 50 nº 4 Agosto 2006
content but also on its bioavailability, solubility and
salt form. Finally, the effect of dietary oxalate on urine
oxalate critically depends upon calcium intake since
decreasing calcium load in the intestinal lumen will
increase the concentration of free oxalate anions avail-
able for absorption (56), as mentioned above. In a
previous evaluation of our group (62), a 2-fold
increase in oxalate intake produced a significant 20%
increase in oxaluria not observed when Ca was con-
sumed simultaneously. Therefore, calcium and
oxalate must be maintained in balance during meals.
As urinary oxalate is also derived from the breakdown
of ascorbic acid, the use of vitamin C supplementation
poses some threat to calcium oxalate SF patients. We
have observed a significant increase in mean urinary
oxalate in SF patients receiving either 1 g or 2 g of
supplement (63). The nutrient that clearly has univer-
sal effects on most of the urinary parameters involved
in stone formation is protein. High protein intake of
animal origin, especially red meat, contributes to
hyperuricosuria (purine overload), hyperoxaluria
(higher oxalate synthesis), hypocitraturia (higher cit-
rate tubular reabsorption) and hypercalciuria (higher
bone resorption; lower tubular calcium reabsorption
to buffer the acid load provided by meat; elevated cal-
cium filtered load; nonreabsorbable calcium salts).
Moderate protein restriction is able to reduce urinary
oxalate, phosphate, hydroxyproline, calcium, and uric
acid and to increase citrate excretion, as reported
(60). The effect of sodium chloride (NaCl) intake on
increasing calcium excretion is well established. Every
100 mmol increase in dietary sodium results approxi-
mately in a 25 mg rise in urinary calcium. The adverse
effects of a high salt intake also contribute to bone
loss. In a previous evaluation by our group (64), a
multiple regression analysis has suggested that a high
NaCl intake (≥ 16 g/day) was the single variable that
was predictive of risk of low bone mineral density in
85 CSF patients (odds ratio: 3.8) after adjustments
for age, weight, body mass index, duration of stone
disease, calcium and protein intakes and urinary calci-
um citrate and uric acid. Low potassium intake may
increase the relative risk for stone formation (59) due
to an increase in urinary calcium and a decrease in uri-
nary citrate.
Table 2 summarizes the general dietary recom-
mendations for SF patients. Whenever possible, they
should be tailored to the specific underlying metabol-
ic disturbance and also to the individual dietary habit,
to ensure compliance.
DRUG TREATMENT
Thiazide diuretics
Thiazide lowers urine calcium resulting in a fall in calci-
um oxalate and calcium phosphate supersaturation.
Reduction of calciuria is attributed to enhanced reab-
sorption of calcium on the renal distal convolute tubule
but very recent and compelling data show that
enhanced passive Ca2+ transport in the proximal tubule
rather than active Ca2+ transport in distal convolution
explains thiazide-induced hypocalciuria (65). Doses of
either chlorthalidone or hydrochlorothiazide should be
no more than 25 mg/day to avoid adverse effects.
Indapamide, a thiazide-like agent is also effective.
Allopurinol
Allopurinol blocks uric acid production, reducing het-
erogeneous nucleation of calcium oxalate by both uric
acid and monosodium urate. In addition, the adsorp-
tion of normally occurring macromolecular inhibitors
of calcium oxalate crystallization by uric acid or mono-
sodium urate could be possibly averted when using
this drug. However, Allopurinol (100 to 300 mg/day)
is indicated only when hyperuricosuria is the only
metabolic abnormality. On the other hand, alkali ther-
apy with potassium citrate may also be beneficial, since
raising urinary pH will help solubilizing uric acid con-
verting it into potassium urate.
Potassium citrate
Potassium citrate reduces urinary saturation of calcium
salts by complexing calcium and reducing ionic calci-
um concentration. Due to its alkalinizing effect, it also
increases the dissociation of uric acid, lowers the
amount of poorly soluble undissociated uric acid,
reducing the propensity to form uric acid stones. The
induced decline of urinary calcium during the early
period of treatment represents a potential additional
Table 2. Dietary recommendations in renal stone disease.
Adequate dietary calcium intake (calcium and oxalate intakes must be in balance)
Reduce animal protein intake
Reduce salt intake
Increase fruits and vegetables intake (rich in potassium)
Increase fluid intake (at least > 2L/day)
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advantage of the drug. Therefore, potassium citrate
seems to be effective in conditions of hypocitraturia,
hypercalciuria, or hyperuricosuria and also in distal
RTA patients, due to the need of alkalinization in the
latter. Potassium citrate is preferable to sodium citrate
in the prevention of urolithiasis, in doses ranging from
30 to 60 mE/day. However, adverse effects of gas-
trointestinal origin including epigastric pain, abdomi-
nal distention or diarrhea are common. Promising
results with the use of other citrate salts such as potas-
sium-magnesium, not yet approved by the Food and
Drug Administration, have also been shown.
Other therapeutic agents
Potassium-acid phosphate and magnesium hydroxide
were shown to have little or no effect on prevention of
stone formation. A neutral potassium phosphate
preparation was shown to be better than placebo in
reducing calcium excretion and raising urinary
inhibitors of stone formation, hence inhibiting CaOx
crystal agglomeration and spontaneous nucleation on
brushite. Pak et al. (18) also suggested a nonselective
therapy, based on evidences from some of the phar-
macological trials, about the beneficial and protective
effects of drugs in stone recurrence rates observed in
patients not categorized according to different urinary
derangements hence not being influenced by the base-
line urinary chemistry. Overall, potassium citrate rep-
resents the most suitable drug for such unselective
treatment because of its indications for hypocitraturic,
hypercalciuric, hyperuricosuric and dRTA patients. On
the other hand, identification of abnormal risk factors
for urinary stones is still important to rule out sec-
ondary causes of nephrolithiasis, such as cystinuria,
hyperoxaluria, renal tubular acidosis and infection
stones (18). Among all of these examples, cystinuria,
the rarest, represents the single entity for which an
actual specific therapy with cystine-binding thiol drugs
to solubilize cystine (alphamercaptoproprionylglycine
or tiopronin, d-penicillamine or angiotensin converting
enzyme inhibitors) would be warranted, despite the
need for a vigorous increase in the amount of fluid
intake and alkalinizing therapy with potassium citrate
as well. Treatment of primary hyperoxaluria consists of
pyridoxine, which facilitates the conversion of glyoxy-
late to glycine. In cases of mild, non-genetic secondary
hyperoxaluria, in addition to dietary manipulation,
there have been new therapeutic perspectives concern-
ing the use of intestinal colonization with the oxalate-
degrading bacteria Oxalobacter formigenes or other
lactic-acid bacteria (66). The single contraindication
for potassium citrate would be urinary tract infection
because of the alkalinizing properties of the com-
pound. Antibiotics should rather be prescribed in such
cases. Complete removal of struvite infection stones
(staghorn calculi) is an important goal to eradicate
causative organisms, relieve obstruction, prevent fur-
ther stone growth and associated infection and pre-
serve kidney function. The use of acetohydroxamic
acid, a bacterial urease inhibitor, may help to reduce
struvite calculi growth but the prevalence of adverse
reactions is very high. The treatment of Primary
Hyperparathyroidism is surgical.
Table 3 lists the most common pharmacologi-
cal agents prescribed according to the metabolic dis-
turbance as discussed earlier. The results of the
majority of clinical trials about medical treatment are
summarized in recent update articles (2,14,61). A
reconsideration of the 1988 National Institute of
Health (NIH) Consensus Statement on prevention
and treatment of kidney stones had been well cov-
ered elsewhere (66).
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